Malignant Mesothelioma Clinical Trial
Official title:
Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB 30107
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the
laboratory may help doctors learn more about cancer and identify biomarkers related to
cancer.
PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in
patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.
OBJECTIVES:
- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial
growth factor receptor I, fibroblast growth factor, transforming growth factor, and
mesothelin portend a poor prognosis in patients with unresectable malignant mesothelioma
treated with vatalanib on protocol CALGB-30107.
- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial
growth factor receptor I, fibroblast growth factor, transforming growth factor, and
mesothelin correlate with response or stable disease in these patients.
OUTLINE: Serum samples previously obtained from patients on protocol CALGB-30107 are tested
for levels of thrombospondin I serum, vascular endothelial growth factor receptor I,
fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked
immunosorbent assays (ELISA).
PROJECTED ACCRUAL: A total of 47 specimens will be accrued for this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06057935 -
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
|
Phase 2 | |
| Completed |
NCT00075699 -
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 3 | |
| Completed |
NCT00821860 -
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
|
Phase 3 | |
| Completed |
NCT00004033 -
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
| Active, not recruiting |
NCT03678350 -
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
|
Phase 1 | |
| Recruiting |
NCT02580747 -
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
|
Phase 1 | |
| Completed |
NCT00398138 -
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
|
Phase 1 | |
| Completed |
NCT00019825 -
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
|
Phase 1 | |
| Active, not recruiting |
NCT00030459 -
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
| Completed |
NCT00004183 -
Capecitabine in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
| Completed |
NCT00005636 -
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
|
Phase 3 | |
| Completed |
NCT00004254 -
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
|
Phase 2 | |
| Completed |
NCT00004920 -
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
|
Phase 3 | |
| Completed |
NCT00334594 -
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
| Completed |
NCT01291420 -
Dendritic Cell Vaccination for Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT01649024 -
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
|
Phase 2 | |
| Completed |
NCT00372840 -
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
|
N/A | |
| Completed |
NCT00513877 -
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
| Active, not recruiting |
NCT00253409 -
Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
|
N/A |